Ebola Treatment Research: Advancements in Monoclonal Antibodies and Antivirals

Clinical trials for Ebola virus disease (EVD) treatments, including the monoclonal antibody MBP134 and the antiviral drug remdesivir, have evolved significantly since the landmark PALM trial conducted in the Democratic Republic of the Congo (DRC) during the 2018–2020 outbreak. According to the World Health Organization (WHO), the development of targeted therapeutics has shifted the prognosis for patients from near-certain fatality to high rates of survival when administered early in the course of infection.

The Evolution of Ebola Therapeutics

The landscape of Ebola treatment changed in 2019 when researchers announced preliminary results from the PALM trial. This study, which took place in the Ituri and North Kivu provinces of the DRC, evaluated four experimental therapies: ZMapp, remdesivir, mAb114, and REGN-EB3. The National Institutes of Health (NIH) reported that patients receiving either mAb114 or REGN-EB3 had significantly higher survival rates compared to those receiving ZMapp or remdesivir. Based on these findings, the Data and Safety Monitoring Board recommended that all patients in the trial be transitioned to the more effective treatments.

Following this study, the U.S. Food and Drug Administration (FDA) approved Inmazeb (REGN-EB3) in 2020, a combination of three monoclonal antibodies. Shortly thereafter, the FDA approved Ebanga (ansuvimab-zykl), which is the single monoclonal antibody known as mAb114. These treatments work by binding to the glycoprotein on the surface of the Ebola virus, preventing it from entering the host’s cells.

Understanding MBP134 and Antiviral Mechanisms

While monoclonal antibodies serve as the current standard of care, research into broader-spectrum antivirals continues. MBP134 is a cocktail of two monoclonal antibodies designed to provide wider coverage against various species of the Ebolavirus genus. Unlike single-target therapies, MBP134 aims to neutralize the virus even if it undergoes genetic mutation.

Remdesivir, originally developed as a broad-spectrum antiviral, functions differently. According to the Centers for Disease Control and Prevention (CDC), remdesivir is a nucleoside analog that inhibits the viral RNA-dependent RNA polymerase. While it showed promise in laboratory settings, its performance in the 2018–2020 clinical trials was less effective than the antibody-based therapies, leading researchers to prioritize the development of monoclonal combinations for acute Ebola management.

Clinical Trial Outcomes and Public Health Impact

The success of the 2018–2020 trials demonstrated that early intervention is critical. Because Ebola virus disease progresses rapidly, the time between the onset of symptoms and the administration of treatment determines the likelihood of survival.

Key Facts on Ebola Treatment

• Standard of Care: Inmazeb and Ebanga are currently the primary FDA-approved treatments for EVD.
• Mechanism: These treatments are monoclonal antibodies that block the virus from entering human cells.
• Early Detection: Survival rates increase dramatically when patients receive treatment shortly after testing positive for the virus.
• Ongoing Research: Scientists continue to study next-generation antibodies, such as MBP134, to ensure efficacy against potential future variants of the virus.

The transition from experimental trials to standardized, life-saving care marks a major milestone in infectious disease response. Future efforts, as outlined by the WHO R&D Blueprint, remain focused on ensuring these treatments are accessible in remote areas where outbreaks most frequently occur. By integrating rapid diagnostic testing with the deployment of monoclonal therapies, health authorities aim to contain outbreaks more efficiently and reduce the mortality rate of the disease significantly.